Nobelpharma America is introducing Hyftor (sirolimus topical gel) 0.2%, the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex for patients 6 years and older.
The company made the introduction at the 2022 World TSC Conference at the Hilton Anatole Hotel in Dallas from July 28-31, 2022.
TSC is a rare genetic disease that affects approximately one in 6,000 live births. Nearly one million people worldwide are estimated to have TSC, with approximately 50,000 in the United States. TSC causes non-cancerous tumors, or hamartomas, to form in vital organs, including the skin.
It may also cause facial angiofibromas, which are pink or red bumps usually located on the cheeks, nose and chin that may cause bleeding, itching, redness and significant disfiguration without treatment. Many individuals with TSC also present with autism, epilepsy and other neuropsychiatric disorders.
"We anticipate that we will be able to have robust discussions with healthcare professionals and individuals with TSC who are interested in learning more about Hyftor," said Yoshiki Kida, president and CEO of Nobelpharma America. "We also will have the opportunity to explain the services Nobelpharma will offer the community through our new patient access program, Nobelpharma Connect."
Nobelpharma Connect is a patient hub where patients may learn about eligibility and enrollment in access programs including assistance program, copay program and other support services.
Nobelpharma will begin providing Hyftor through a network of specialty pharmacies in August.
"Nobelpharma is committed to advancing the scientific understanding of TSC and delivering new options to individuals and families impacted by this disease," Kida said. "As we introduce Hyftor, we look forward to strengthening our relationships within the patient community, maintaining a dialogue and listening to their experiences to help shape the future of research and treatment."